期刊
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
卷 41, 期 2, 页码 623-634出版社
KARGER
DOI: 10.1159/000457933
关键词
P38 MAPK; SB203580; Total parenteral nutrition; Intestinal barrier; Lipoapoptosis
资金
- Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition [14DZ2272400]
- Shanghai Municipal Commission of Health and Family Planning [201640264]
- National Natural Science Foundation of China [81400861, 81630039]
Background & Aims: Our previous studies have provided evidence that p38 mitogenactivated protein kinase (MAPK) is involved in total parenteral nutrition (TPN)-associated complications, but its exact effects and mechanisms have not been fully understood. This study aimed to evaluate the roles of p38 MAPK inhibitor SB203580 in the TPN-induced loss of intestinal barrier function and liver disease. Methods: A rodent model of TPN was used to analyze the roles of SB203580 in TPN-associated complications. Intestinal barrier function was evaluated by transepithelial electrical resistance (TER) and paracellular permeability in Caco-2 cells. The palmitic acid (PA) was used to induce hepatic lipoapoptosis in vitro. The lipoapoptosis was detected using Caspase-3/7 and lipid staining. Results: In the present study, we showed that SB203580 treatment significantly suppressed TPN-mediated intestinal permeability in rats. SB203580 treatment significantly inhibited IL-1 beta-induced an increase in tight junction permeability of Caco-2 cells via repressing the p38/ATF-2 signaling. Unexpectedly, SB203580 treatment enhanced hepatic lipoapoptosis in the model of TPN. Palmitic acid (PA)-induced hepatic lipoapoptosis in human liver cells was significantly augmented by the SB203580 treatment. Conclusions: We demonstrate that the p38 MAPK inhibitor SB203508 ameliorates intestinal barrier function but promotes hepatic lipoapoptosis in model of TPN. (C) 2017 The Author(s) Published by S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据